International AIDS Vaccine Initiative — CureCurrent

Published trials46

Recruiting shown1

Roles2

SourceClinicalTrials.gov

Clinical trials

46 shown

A Trial of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine, Administered to Healthy Adults Living Without and With HIV.NCT06617091 · lead sponsor · 2025-07-28

Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa.NCT06694753 · lead sponsor · 2025-12-15

ACTIVE_NOT_RECRUITING

Mosaic HIV-1 Envelope Trimer Immunogens Administered to People Living with HIV (PLWH) in AfricaNCT06449196 · lead sponsor · 2024-08-27

A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, AdjuvantedNCT05983874 · lead sponsor · 2024-04-16

A Clinical Trial to Evaluate the Safety and Immunogenicity of a Prophylactic HIV Vaccine CandidateNCT05863585 · lead sponsor · 2023-06-01

A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)NCT05001373 · lead sponsor · 2021-11-12

A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 Gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected AdultsNCT04224701 · lead sponsor · 2020-08-01

Study to Evaluate H56:IC31 in Preventing Rate of TB RecurrenceNCT03512249 · lead sponsor · 2019-01-31

A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected AdultsNCT03721510 · lead sponsor · 2018-12-03

A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected AdultsNCT03699241 · lead sponsor · 2018-12-03

A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, AdjuvantedNCT03547245 · lead sponsor · 2018-06-15

A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected AdultsNCT03205917 · lead sponsor · 2017-10-23

Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected AdultsNCT02960581 · lead sponsor · 2016-11-01

Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 VaccineNCT02366013 · lead sponsor · 2015-01-01

A Phase 1, Randomized, Blinded, Dose-escalation Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults.NCT01937455 · lead sponsor · 2014-09-01

Safety and Immunogenicity Study of SeV-G(NP) HIV Vaccine Administered Intranasally and Ad35-GRIN HIV Vaccine Given Intramuscularly in Prime-Boost Regimens in HIV-Uninfected VolunteersNCT01705990 · lead sponsor · 2013-03-01

Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected VolunteersNCT01496989 · lead sponsor · 2011-12-01

Safety and Immunogenicity Study of 2 Investigational Preventive HIV VaccinesNCT01264445 · lead sponsor · 2011-02-01

Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected AdultsNCT01215149 · lead sponsor · 2010-10-01

A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, AfricaNCT00931346 · lead sponsor · 2009-10-01

A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-Risk Populations in Kenya, AfricaNCT00971230 · lead sponsor · 2009-10-01

A Trial to Evaluate Ad35-GRIN/ENV HIV Vaccine in Healthy Adult VolunteersNCT00851383 · lead sponsor · 2009-03-01

Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV VaccineNCT00902824 · lead sponsor · 2008-11-01

Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) CapsidNCT00888446 · lead sponsor · 2005-10-01

Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected AdultsNCT00252148 · lead sponsor · 2005-01-01

Safety and Immunogenicity Study of tgAAC09, a Gag-PR-RT AAV HIV VaccineNCT00482027 · lead sponsor · 2003-12-01

Safety and Immunogenicity of a Plasmid HIV Vaccine in HIV Uninfected AdultsNCT00249106 · lead sponsor · 2003-12-01

A Phase IIA Trial to Evaluate the Safety and Immunogenicity of a DNA HIV-1 Vaccine Followed by an MVA HIV-1 Vaccine in HIV-uninfected VolunteersNCT01371175 · lead sponsor · 2003-04-01

Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their LifeNCT07655128 · collaborator · 2027-01-01

NOT_YET_RECRUITING

Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their Life (2)NCT07655141 · collaborator · 2027-01-01

NOT_YET_RECRUITING

A Study to Test Three Experimental HIV Vaccines in Healthy Adults.NCT04553016 · collaborator · 2021-08-16

Feasibility of Identifying, Enrolling and Following Acute and Early HIV-1 Infected Individuals.NCT05372510 · collaborator · 2021-02-17

A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEPNCT04066881 · collaborator · 2020-12-15

Combinatorial Therapy to Induce an HIV RemissionNCT04357821 · collaborator · 2020-08-01

Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected AdultsNCT04177355 · collaborator · 2020-01-13

10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected AdultsNCT03875209 · collaborator · 2019-04-08

Evaluation of the Effect of Late Boost on HIV-uninfected Vaccines From EV06 TrialNCT03391375 · collaborator · 2017-03-15

Introducing PrEP Into HIV Combination Prevention - KenyaNCT02755350 · collaborator · 2015-08-01

Zambia SiVET MMR Tdap-IPVNCT02589678 · collaborator · 2015-08-01

Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) PreventionNCT02315703 · collaborator · 2014-12-22

Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDSNCT02376582 · collaborator · 2014-09-01

Safety & Immunogenicity of HIV Vaccines in Healthy Kenyan AdultsNCT02099994 · collaborator · 2014-03-01

Targeted Screening of At-Risk Adults for Acute HIV-1 InfectionNCT01876199 · collaborator · 2013-02-01

Study of a Potential Preventive Vaccine Against HIV in Healthy VolunteersNCT00545987 · collaborator · 2007-09-01

Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and AfricaNCT00498056 · collaborator

Safety of and Immune Response to an HIV DNA Plasmid Vaccine Followed by HIV Adenoviral Vector Vaccine in Healthy African AdultsNCT00415649 · collaborator

Sponsor roles

lead sponsor28

collaborator18

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.